vickyhkapi – 第 4 頁

05 4 月 23

Appointment of New Board Members

HKAPI has announced the election of two new members to its Board of Directors. Mr Neo Lam, from Baxter, and Mr Jonathan Chin, from Boehringer Ingelheim, have been elected to join the Board and will serve until the end of this term (2024).

22 3 月 23

週年會員大會完滿結束

本會欣然宣布，香港科研製藥聯會第55屆會員大會，已於2023年3月22日順行舉行。逾60名會員公司代表參與其中，探討及交流行業的挑戰和機遇。

16 2 月 23

HKAPI x HKSTP – How AI is Transforming Drug Discovery and Clinical Trial Design

The "Symposium - How AI is Transforming Drug Discovery and Clinical Trial Design" was a huge success, with drug developers and investors in attendance to learn about the latest AI technologies in drug discovery and clinical development.

13 2 月 23

藥物法規趨勢調查簡介會

香港科研製藥聯會舉辦有關藥物法規趨勢調查的簡介會，吸引超過50名會員出席。

11 1 月 23

《實務守則》導師培訓工作坊2023

More than 260 members attended the Code of Practice Train-the-Trainer Workshop on 11 January 2023 to understand the key changes of the Code and its implications for HKAPI members.

09 1 月 23

委任新董事

香港科研製藥聯會欣然宣布，瑞士諾華製藥(香港)有限公司香港總經理張茂嵩先生，正式加入本會董事會，任命自2023年1月9日起生效。

衞生署與藥劑業界進行會議

1 月 9, 2023
vickyhkapi
No Comments

衞生署與藥劑業界就維持本港含撲熱息痛藥物的穩定供應進行會議。

11 11 月 22

亞洲醫療健康高峰論壇

香港科研製藥聯會很榮幸，獲邀以醫療健康營商諮詢服務區支持夥伴身份，參與由香港特區政府及香港貿易發展區主辦的「亞洲醫療健康高峰論壇」。

07 10 月 22

特別會員大會2022

An online EGM was called by the HKAPI Board to pass a resolution to adopt the new Code of Practice. It was unanimously adopted by members with immediate effect.

06 9 月 22

委任新董事

香港科研製藥聯會欣然宣布，美國禮來亞洲有限公司總經理（香港及澳門）林建宏先生，正式加入本會董事會，任命自2022年9月6日起生效。